Biggest quarter ahead from the company and peers after the pre clinical success and 8 years of development to this point are trading at 70-100 million market caps. 10 million market cap with 10 million in funding is a joke. The below tells you where this is going. Should be trading at a 60-70 cent share price leading into phase 2 but it’s coming
Ann: Significant Neuroprotection in NYR Preclinical Brain Injury, page-176
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
